Page last updated: 2024-12-05

vinca

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Vinca: A plant genus of the family Apocynaceae. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
VincagenusA plant genus of the family Apocynaceae.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]

Cross-References

ID SourceID
PubMed CID5668
CHEMBL ID1604925
CHEBI ID107202
SCHEMBL ID3767
MeSH IDM0396511

Synonyms (42)

Synonym
LS-14901
nsc-131616
mls000738212 ,
nsc131616
isovincamine
14-epivincamine
eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methyl ester, (3.alpha.,14.alpha.,16.alpha.)-
NCI60_042034
6835-99-0
NSC91998 ,
eburnamenine-14-carboxylic acid,15-dihydro-14-hydroxy-, methyl ester, (3.alpha.,14.beta.,16.alpha.)-
vinca
wln: t d6 b5666 2ab s cn mn&&tttj q2 svo1 sq
OPREA1_175623
smr000528577
CHEBI:107202
AKOS003368707
HMS2269H11
eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methyl ester, (3alpha,14alpha,16alpha)-
einecs 229-915-5
methyl (3alpha,14alpha,16alpha)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylate
FT-0603566
SCHEMBL3767
CHEMBL1604925
eburnamine-14-carboxylic acid,14,15-dihydro-14-hydroxy-, methyl ester,(3.alpha.,14.alpha.,16.alpha.)-
(-)-cis-epivincamine
lsm-18556
Q27185266
DTXSID90274475
SR-01000769143-5
SR-01000769143-6
SR-01000769143-7
SR-01000769143-8
sr-01000769143
BRD-A47175490-001-10-8
ethyl3-(benzyloxy)cyclobutanecarboxylate
methyl (41s,12s,13ar)-13a-ethyl-12-hydroxy-2,3,41,5,6,12,13,13a-octahydro-1h-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate
methyl 15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
SY057985
DTXSID90859660
eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methyl ester, (3alpha,14alpha)
eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methyl ester, (14beta,16alpha)

Research Excerpts

Overview

Vinca minor is a plant from the Apocynaceae family known to produce over 50 monoterpene indole alkaloids. Vincamine is a poorly soluble potent neuroprotector and cerebral vasodilator, used for the treatment for CNS disorders.

ExcerptReferenceRelevance
"Vinca minor is a herbaceous plant from the Apocynaceae family known to produce over 50 monoterpene indole alkaloids (MIAs). "( The ATP binding cassette transporter, VmTPT2/VmABCG1, is involved in export of the monoterpenoid indole alkaloid, vincamine in Vinca minor leaves.
De Luca, V; Demessie, Z; Qu, Y; Woolfson, KN; Yu, F, 2017
)
2.11
"Vinca minor is a plant containing the alkaloid vincamine, which is used in the pharmaceutical industry as a cerebral stimulant and vasodilator. "( Vincamine-producing endophytic fungus isolated from Vinca minor.
Sun, YH; Yin, H, 2011
)
3.25
"Vincamine is a poorly soluble potent neuroprotector and cerebral vasodilator, used for the treatment for CNS disorders. "( Rationale of using Vinca minor Linne dry extract phytocomplex as a vincamine's oral bioavailability enhancer.
Cepek, C; Chierotti, MR; Dall'Acqua, S; Gobetto, R; Grabnar, I; Hasa, D; Perissutti, B; Voinovich, D, 2013
)
2.16

Bioavailability

ExcerptReferenceRelevance
" In some cases, the bioavailability of pure compounds is strongly influenced by the co-administration of other constituents, and in some cases, the so called 'phytocomplex' may act as enhancer of absorption of selected phytochemicals."( Rationale of using Vinca minor Linne dry extract phytocomplex as a vincamine's oral bioavailability enhancer.
Cepek, C; Chierotti, MR; Dall'Acqua, S; Gobetto, R; Grabnar, I; Hasa, D; Perissutti, B; Voinovich, D, 2013
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkaloidAny of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.94330.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency7.06270.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency10.00000.177814.390939.8107AID2147
acid sphingomyelinaseHomo sapiens (human)Potency31.622814.125424.061339.8107AID504937
ClpPBacillus subtilisPotency15.84891.995322.673039.8107AID651965
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency24.84460.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency24.70280.180013.557439.8107AID1460; AID1468
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency19.80030.036619.637650.1187AID2100
runt-related transcription factor 1 isoform AML1bHomo sapiens (human)Potency63.09570.02007.985839.8107AID504374
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
core-binding factor subunit beta isoform 2Homo sapiens (human)Potency63.09570.02007.985839.8107AID504374
importin subunit beta-1 isoform 1Homo sapiens (human)Potency72.33425.804836.130665.1308AID540253; AID540263
snurportin-1Homo sapiens (human)Potency72.33425.804836.130665.1308AID540253; AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency44.66840.425612.059128.1838AID504891
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency44.66845.804816.996225.9290AID540253
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency28.18380.075215.225339.8107AID485360
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency11.22020.00419.962528.1838AID2675
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency11.22020.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Caspase 6, apoptosis-related cysteine peptidaseHomo sapiens (human)AC5021.72000.063611.235844.9700AID720632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (159)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (30.19)18.7374
1990's0 (0.00)18.2507
2000's30 (18.87)29.6817
2010's58 (36.48)24.3611
2020's23 (14.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.64 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index223.94 (26.88)
Search Engine Supply Index3.75 (0.95)

This Compound (69.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.60%)5.53%
Reviews4 (2.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.60%)0.25%
Other160 (96.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]